OmniAb (OABI) Net Income (2021 - 2026)
OmniAb (OABI) reported Net Income of -$7.7 million for Q1 2026, up 57.65% year-over-year from -$4.9 million in Q1 2025, and up 45.64% quarter-over-quarter from -$14.2 million in Q4 2025.
OmniAb (OABI) Net Income (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Net Income data on file, last reported at -$7.7 million in Q1 2026.
- Net Income for Q1 2026 came in at -$7.7 million, up 57.65% year-over-year; the trailing twelve-month figure through Mar 2026 was -$54.3 million (up 11.4% YoY), and the FY2025 annual result was -$64.8 million, down 4.43% from the prior year.
- Net Income grew to -$7.7 million in Q1 2026 per OABI's latest filing, from -$14.2 million in the prior quarter.
- Over five years, Net Income peaked at $6.8 million in Q4 2022 and troughed at -$19.0 million in Q1 2024.
- A 5-year average of -$12.2 million and a median of -$14.1 million in 2023 frame the typical range for Net Income.
- On a YoY basis, Net Income climbed as much as 119.25% in 2022 and fell as far as 470197.48% in 2022.
- A 5-year view of Net Income shows it stood at $6.8 million in 2022, then plunged by 306.06% to -$14.1 million in 2023, then rose by 7.01% to -$13.1 million in 2024, then decreased by 8.5% to -$14.2 million in 2025, then surged by 45.64% to -$7.7 million in 2026.
- Business Quant data shows OABI's Net Income at -$7.7 million in Q1 2026, -$14.2 million in Q4 2025, and -$16.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | -7.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.71 Mn |
| Dec 31, 2025 | -14.18 Mn |
| Sep 30, 2025 | -16.53 Mn |
| Jun 30, 2025 | -15.88 Mn |
| Mar 31, 2025 | -18.20 Mn |
| Dec 31, 2024 | -13.07 Mn |
| Sep 30, 2024 | -16.37 Mn |
| Jun 30, 2024 | -13.63 Mn |
| Mar 31, 2024 | -18.96 Mn |
| Dec 31, 2023 | -14.05 Mn |
| Sep 30, 2023 | -15.74 Mn |
| Jun 30, 2023 | -14.73 Mn |
| Mar 31, 2023 | -6.10 Mn |
| Dec 31, 2022 | 6.82 Mn |
| Sep 30, 2022 | -12.60 Mn |
| Jun 30, 2022 | -10.28 Mn |
| Mar 31, 2022 | -6.28 Mn |
| Dec 31, 2021 | -35.43 Mn |
| Sep 30, 2021 | -170,579.00 |
| Jun 30, 2021 | -2,185.00 |